In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.
List view / Grid view
Filter the results
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.